RESI Innovation Challenge

LSN invites all global early-stage companies across Biotech, Medtech, Diagnostics & Digital Health to apply for the RESI Innovation Challenge. Selected companies will showcase their technology in the exhibit hall and gain more visibility from the early-stage investors in attendance.

If you are a scientist-entrepreneur or fundraising CEO starting to accumulate compelling proof-of-concept animal data or early stage clinical data, the RESI Innovation Challenge is for you. The 30 most innovative applicants will be hand selected by Life Science Nation’s internal scientific review board to be part of the RESI Innovation Challenge, presenting their technologies in an exhibition-style format throughout the full-day conference. Presenters will gain additional exposure to investors and potential partners by showcasing their companies and products in a poster format. Unlike traditional 5- to 15-minute pitch presentations that do not allow any real interaction and provide no actionable feedback from investors, the RESI Innovation Challenge enables executives to pitch directly to attendees, generating more in-depth conversations with more investors, more frequently throughout the event.

Apply to RESI Innovation Challenge

APPLICATION DEADLINE: DEC. 72018

To add some friendly competition to the mix, the RESI Innovation Challenge invites all attendees to participate in a virtual investment contest. At the start of the day, each attendee will receive “RESI Cash” to allocate to the entrepreneurs whose technologies they expect will be most influential. The capital invested will be tallied up and the top three winners will receive prizes and be featured in our RESI newsletter recap that will go out to LSN’s 23,000 newsletter readership. Whether you are an investor, an entrepreneur, or a service provider, make sure you check out the exhibit hall to meet with some of the top innovators in the field and invest your “RESI Cash.” We will see you there!

West Coast Innovators Pitch Challenge

All eligible tech hub constituents from the West Coast are also invited to apply to the West Coast Innovators Pitch Challenge and have the chance to pitch your technologies to a panel of investors.

  • Open to the constituents of West Coast incubators, tech transfer offices, universities, hospitals, and research labs .
  • Top 8 ranked companies of the West Coast tech hubs will present their technology as a 5-minute pitch to a panel of early-stage investors.
  • Boost your exposure to 500+ investors
  • All finalists will be featured in the program guide, on the RESI website and announced in LSN’s newsletter to a readership of 23,000+
  • It is FREE to apply
Apply Now

APPLICATION DEADLINE: DEC. 72018

RESI NYC 2018 Innovation Challenge Winners

First Prize:

Promaxo is a medical technology company that develops and commercializes office-based modular MRI and MRI based technologies. The Company is currently focused on advancing the solutions for prostate disease management and other urology and pelvic conditions.

Second Prize:

Keriton Kare is a NICU feeding management, lactation analytics and patient engagement platform with end-to-end automation to improve process efficiency, reduce risk of erroneous feeds and enhance breastfeeding outcomes through a suite of mobile applications – Kare Mom and Kare Nurse.

Third Prize:

Thermaquil discovered a completely new way of managing pain. We are first addressing the heart of the opioid crisis by treating post-surgical pain. Our minimally invasive device will be inserted at the time of surgery by the surgeon or anesthesiologist and later pulled out by the patient’s physician when recovery is complete. Thermaquil’s system creates a virtual filter across any nerve that allows patients to dial-in 0-100% how much of the nerve’s firing gets through by gently warming and cooling a short section of the nerve. Reversible thermal nerve blocks are a new mechanism of pain treatment distinct from drugs and electric stimulation. Thermaquil seeks to reduce or eliminate the need for opioids through non-addictive thermal nerve blocks.